Serum levels of vaspin and visfatin in patients with coronary artery disease—Kozani study

Kadoglou, Nikolaos P.E.; Gkontopoulos, Argirios; Kapelouzou, Alkistis; Fotiadis, Grigorios; Theofilogiannakos, Efstratios K.; Kottas, George; Lampropoulos, Stilianos

doi:10.1016/j.cca.2010.09.012

Cited by 106 publications

(83 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In addition, the levels of vaspin elevated in patients with acute ischemic stroke, but did not correlate with the severity of coronary stenosis (42). However, lower vaspin levels were reported in individuals with coronary artery disease and these correlated with disease severity (40). Vaspin levels increased in overweight individuals and associated positively with age, female gender, and BMI.…”

Section: Discussionmentioning

confidence: 96%

See 1 more Smart Citation

The levels of visceral adipose tissue-derived serpin, omentin-1 and tumor necrosis factor-α in the gingival crevicular fluid of obese patients following periodontal therapy

et al. 2016

View full text Add to dashboard Cite

The aim of this clinical study was to determine levels of visceral adipose tissue-derived serpin (vaspin), omentin-1, and tumor necrosis factor-alpha (TNF-α) in the gingival crevicular fluid (GCF) of obese and non-obese periodontitis patients following nonsurgical periodontal therapy. Seventy-six subjects were separated into four groups according to periodontal and anthropometric measurements: a periodontal-healthy group, a chronic periodontitis (CP) group, a periodontal-healthy with obesity group, and a CP with obesity group. Nonsurgical periodontal treatment was administered to periodontitis patients. Before treatment and at 6 weeks after treatment, GCF samples were analyzed and clinical periodontal parameters were examined. Enzyme-linked immunosorbent assays were used to measure the levels of vaspin, omentin-1, and TNF-α. Obese and non-obese CP patients displayed higher levels of vaspin and TNF-α (P < 0.008), which declined following treatment (P < 0.025), and lower omentin levels (P < 0.008), which increased after treatment (P < 0.025). There was a negative correlation between the total amount of vaspin and omentin-1 in all groups. Obese and non-obese patients had opposing levels of vaspin and omentin-1 in the GCF; therefore, these may represent diagnostic and prognostic indicators of periodontal disease and therapeutic outcome. (J Oral Sci 58, [465][466][467][468][469][470][471][472][473] 2016)

show abstract

Section: Discussionmentioning

confidence: 96%

“…Changes in vaspin levels have been investigated in many diseases (38)(39)(40)(41)(42). Vaspin was associated with obesity, type 2 diabetes mellitus, rheumatoid arthritis, and systemic inflammation (39,43).…”

Section: Discussionmentioning

confidence: 99%

The levels of visceral adipose tissue-derived serpin, omentin-1 and tumor necrosis factor-α in the gingival crevicular fluid of obese patients following periodontal therapy

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Several studies have shown that increased visfatin is associated with coronary artery disease in patients with asymptomatic coronary artery disease, patients devoid of risk factors presenting especially with acute coronary syndrome (26,27) . Various disorders may lead to altered plasma levels of visfatin and visfatin plasma concentrations may be related with lipid metabolism (28) and the inflammatory response (29) .…”

Section: Discussionmentioning

confidence: 99%

Serum Visfatin Levels and Coronary Artery Disease

Gürsoy¹,

Duygu²,

Hökenek³

et al. 2014

Khj

View full text Add to dashboard Cite

Introduction: Adipose tissue is not only source of energy but also an active endocrine organ serving function by secreting bioactive molecules called adipokines. Visfatin is a recently discovered adipokine and is proposed to play role in inflammatory and atherosclerotic states. We aimed to investigate the association of visfatin with coronary artery disease (CAD). Patients and Methods: Twenty patients undergoing coronary artery bypass grafting due to CAD were compared with 20 individuals without CAD angiographically. Gender, age, body mass index, and serum visfatin levels were compared between the two groups. Relationship of visfatin levels and severity of CAD, cross-clamp and cardiopulmonary bypass times were also investigated in the study group. Results: Age, gender, BMI, and blood pressures were not significantly different between the groups. There was significant difference in serum visfatin levels between the two groups (47.31±33.03 ng/mL and 9.04±7.18 ng/mL, p=0.0001). A strong correlation between the Gensini score and pre-operative visfatin levels (r=0.81; p=0.0001) was observed for the study group. No correlation was detected between the visfatin level and cardiopulmonary bypass and cross clamp times. Conclusion: Increased visfatin levels may be associated with inflammation and atherosclerotic cardiovascular diseases. Circulating visfatin level is increased in patients undergoing coronary artery bypass grafting. Further studies are warranted to determine the predictive value of serum visfatin as a biomarker and potential therapeutic target for metabolic and cardiovascular diseases. Key Words: Adipose tissue; adipokine; visfatin; atherosclerosis; coronary artery disease Giriş: Yağ dokusu yalnızca enerji kaynağı olmayıp aynı zamanda adipokin olarak adlandırılan biyoaktif maddeleri salgılayan bir endokrin organdır. Visfatin son dönemlerde keşfedilen, inflamasyon ve ateroskleroz ile ilişkilendirilen bir adipokindir. Bu çalışmada visfatinin koroner arter hastalığı ile ilişkisini araştırmayı amaçladık. Hastalar ve Yöntem: Koroner arter hastalığı sebebiyle koroner arter baypas greftleme planlanan 20 hasta anjiografik olarak koroner arter hastalığı olmayan 20 bireyle kıyaslandı. Cinsiyet, yaş, vücut kitle indeksi ve serum visfatin seviyesi gruplar arasında karşılaştırıldı. Visfatin seviyesinin koroner arter hastalığının ciddiyeti, aortic kros klemp zamanı ve kardiyopulmoner baypas zamanı ile ilişkisi de incelendi. Bulgular: Gruplar arasında yaş, cinsiyet, vücut kitle indeksi ve kan basınçları arasında fark saptanmadı. Serum visfatin seviyeleriyse anlamlı farklı bulundu (47,31±33,03 ng/ml ve 9,04±7,18 ng/ml, p=0,0001). Gensini skoru ile preoperative visfatin seviyesi arasında güçlü korelasyon saptandı (r=0,81; p=0,0001). Visfatin seviyesi ile kardiyopulmoner baypas ve aortic kros klemp zamanı arasında ilişki saptanmadı. Sonuç: Artmış serum visfatin seviyesi inflamasyon ve aterosklerotik kardiyovasküler hastalıklarla ilişkili olabilir. Dolaşımdaki visfatin seviyesi koroner arter baypas greftleme yapılan hastalarda...

show abstract

“…Visfatin is a newly identified proinflammatory adipokine that has been linked to CAD, including MI (Kadoglou et al, 2011). Visfatin is a 52-to 55-kDa protein that was originally cloned as a growth factor that enhanced the effects of stem cell factor and IL-7 on colony formation by early-stage B cells (Yan et al, 2010).…”

Section: Introductionmentioning

confidence: 99%

“…Recent studies have indicated that the plasma visfatin level correlates with the serum levels of CRP, IL-6, and TNF-α, indicating that circulating visfatin may reflect an individual's inflammatory status. The plasma visfatin level may influence the risk of CAD (Liu et al, 2009;Kadoglou et al, 2011;Wang et al, 2011a). Therefore, it was hypothesized that plasma visfatin could be functional and might be associated with the development of MI.…”

Section: Introductionmentioning

confidence: 99%

An elevated plasma level of visfatin increases the risk of myocardial infarction

Yang

Tao

et al. 2014

Genet. Mol. Res.

View full text Add to dashboard Cite

ABSTRACT. Visfatin, an adipocytokine involved in metabolic and immune disorders, plays an important role in the etiology of cardiovascular disease. Recent evidence has shown that an elevated plasma level of visfatin may increase the risk of myocardial infarction (MI), but individual published studies have shown inconclusive results. This study aimed to obtain a more precise estimate of the association between the plasma visfatin level and MI risk through a detailed meta-analysis of studies published in peer-reviewed journals. A literature search of articles published before May 1, 2013 was performed on the PubMed, Embase, Web of Science, and China BioMedicine databases. Crude standardized mean differences (SMDs) with 95% confidence intervals (CI) were calculated. Eleven case-control studies comprising 362 MI patients and 322 healthy controls were included. The meta-analysis revealed that an elevated plasma level of visfatin was associated with an increased risk of MI (SMD = 3.82, 95%CI = 2.67-4.98, P < 0.001). Further stratification based on the source of the controls showed that an elevated plasma 8587 Plasma visfatin level and MI risk ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 13 (4): 8586-8595 (2014) level of visfatin was significantly associated with increased risk of MI in both hospital-based and population-based studies (SMD = 4.12, 95%CI = 2.23-6.01, P < 0.001 and SMD = 3.65, 95%CI = 2.67-4.98, P < 0.001, respectively). No publication bias was evident in this meta-analysis. In conclusion, the current meta-analysis indicates that an elevated plasma level of visfatin increases the risk of MI. Therefore, plasma visfatin may be a promising biomarker for the diagnosis of MI.

show abstract

Serum levels of vaspin and visfatin in patients with coronary artery disease—Kozani study

Cited by 106 publications

References 29 publications

The levels of visceral adipose tissue-derived serpin, omentin-1 and tumor necrosis factor-α in the gingival crevicular fluid of obese patients following periodontal therapy

The levels of visceral adipose tissue-derived serpin, omentin-1 and tumor necrosis factor-α in the gingival crevicular fluid of obese patients following periodontal therapy

Serum Visfatin Levels and Coronary Artery Disease

An elevated plasma level of visfatin increases the risk of myocardial infarction

Contact Info

Product

Resources

About